The estimated Net Worth of William P. Mr. Burke is at least $18 Million dollars as of 1 September 2024. Mr. Burke owns over 11,904 units of Haemonetics stock worth over $2,068,955 and over the last 8 years he sold HAE stock worth over $13,315,096. In addition, he makes $2,598,210 as Chief Financial Officer and Executive Vice President at Haemonetics.
William has made over 23 trades of the Haemonetics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 11,904 units of HAE stock worth $862,445 on 1 September 2024.
The largest trade he's ever made was selling 41,654 units of Haemonetics stock on 8 October 2019 worth over $5,133,439. On average, William trades about 5,234 units every 76 days since 2016. As of 1 September 2024 he still owns at least 28,557 units of Haemonetics stock.
You can see the complete history of Mr. Burke stock trades at the bottom of the page.
William P. Burke serves as Chief Financial Officer, Executive Vice President of the Company. From July 2014 to July 2016, Mr. Burke served as Chief Integration Officer and Vice President, Integration for Medtronic plc, a global healthcare products company and was a member of its Executive Committee. In that role, Mr. Burke was responsible for ensuring the successful integration of Medtronic with Covidien plc, a global healthcare company, following its acquisition by Medtronic. Prior to joining Medtronic, Mr. Burke spent more than 20 years in finance and business development leadership roles at Covidien, including Chief Financial Officer for Covidien Europe based in Zurich, Vice President of Corporate Strategy and Portfolio Management and Vice President of Financial Planning and Analysis. Previously, Mr. Burke also held key positions within Tyco Healthcare, including the Financial Controller of Valleylab, Managing Director of the Covidien Group in Switzerland and International Controller. He began his career as an auditor with KPMG. Mr. Burke received a Bachelor of Science degree in Business Administration from Bryant College.
As the Chief Financial Officer and Executive Vice President of Haemonetics, the total compensation of William Burke at Haemonetics is $2,598,210. There are 1 executives at Haemonetics getting paid more, with Christopher Simon having the highest compensation of $9,398,200.
William Burke is 52, he's been the Chief Financial Officer and Executive Vice President of Haemonetics since 2016. There are 11 older and 2 younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.
William's mailing address filed with the SEC is C/O AXOGEN, INC. 13631 PROGRESS BLVD., SUITE 400, ALACHUA, FL, 32615.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy, and Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: